NCT04701307 2026-04-22
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT06180356 2026-04-22
ANALLISA
MedSIR
Phase 2 Recruiting
NCT03431350 2026-04-13
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT05335993 2026-04-03
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03601923 2026-03-25
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed